Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Pays Affymetrix $2M in Stock As Part of Dx Deal

NEW YORK (GenomeWeb News) - Epigenomics yesterday paid Affymetrix €1.6 million ($2 million) worth of stock as part of the upfront payments the firms agreed to under their diagnostic alliance announced in June, the company said today.
 
As part of the deal, Epigenomics issued 304,791 novel non par value bearer shares valued at €5.22 each. After registration, the value of Epigenomics' outstanding common shares will increase to €16.7 million from €16.4 million.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.